Loading...
Consider the following three related observations: (1) when patients initiate urate-lowering therapy for gout, a concurrent course of prophylactic colchicine for several months lowers the incidence of acute gout flares; (2) gout flares have been associated with transient increases in adverse cardiovascular (CV) events; and (3) in at least one trial, colchicine lowered the incidence of adverse CV events in patients with chronic coronary artery disease (NEJM JW Cardiol Oct 2020 and N Engl J Med 2020; 383:1838). These observations led researchers to examine whether adding colchicine prophylactically when urate-lowering therapy was initiated might lower short-term risk for adverse CV events in patients with gout.
This retrospective study involve…